Pulse Biosciences (PLSE) clarifies disclosure on CCO Kevin Danahy’s resignation

Rhea-AI Filing Summary

Pulse Biosciences, Inc. filed an amended current report to update a prior disclosure about a leadership change. The amendment notes that on February 27, 2026, Chief Commercial Officer Kevin P. Danahy notified the company that he was resigning, effective immediately. The amended report states it was filed to remove two sentences from the original filing, but does not change the core fact of his immediate departure. The company continues to be led by President and Chief Executive Officer Paul A. LaViolette, who signed the report.

Insights

Corporate governance analyst

Leadership change confirmed; amendment appears largely administrative.

Pulse Biosciences confirms that Chief Commercial Officer Kevin P. Danahy resigned effective immediately on February 27, 2026. The amended report states it was filed to remove two sentences from the earlier disclosure, suggesting a clarification rather than a change in substance.

From a governance standpoint, the key fact is the immediate departure of a senior commercial leader, which may matter in execution of growth plans. However, no additional detail on succession, reasons for resignation, or business impact is provided in this excerpt.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did Pulse Biosciences (PLSE) disclose in this 8-K/A amendment?

Pulse Biosciences filed an amended current report to update a prior disclosure. It confirms that Chief Commercial Officer Kevin P. Danahy resigned effective immediately on February 27, 2026, and states the amendment was made to remove two sentences from the original filing.

Which executive resigned from Pulse Biosciences (PLSE) according to this filing?

The filing states that Kevin P. Danahy, the Chief Commercial Officer of Pulse Biosciences, gave notice of his resignation effective immediately on February 27, 2026. This confirms a change in the company’s senior commercial leadership team at that time.

When did the Pulse Biosciences (PLSE) Chief Commercial Officer resignation become effective?

According to the filing, Chief Commercial Officer Kevin P. Danahy’s resignation was effective immediately on February 27, 2026. The amended report reiterates this effective date while clarifying the original disclosure by removing two sentences from the prior current report.

Why did Pulse Biosciences (PLSE) file an amended 8-K/A?

Pulse Biosciences filed the amended report to change its earlier current report filed on February 27, 2026. The amendment’s explanatory note states it was submitted specifically to remove two sentences, while leaving the core disclosure about the Chief Commercial Officer’s resignation intact.

Who signed the Pulse Biosciences (PLSE) amended report?

The amended report was signed on behalf of Pulse Biosciences by Paul A. LaViolette. He is identified in the document as the company’s President and Chief Executive Officer and serves as the principal executive officer for purposes of the report’s certification.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 09:21 AM Learn about SEC filing dates

Form 8-K, Danahy Resignation v.3 true 0001625101 0001625101 2026-02-27 2026-02-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 27, 2026

Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware	001-37744	46-5696597
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
601 Brickell Key Drive, Suite 1080
Miami, Florida 33131
(Address of Principal Executive Offices) (Zip Code)
510-906-4600
(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share	PLSE	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note

This Form 8-K/A amends the Current Report on Form 8-K filed by Pulse Biosciences, Inc. (the "Company"') with the U.S. Securities and Exchange Commission on February 27, 2026 to remove two sentences.

Item 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On February 27, 2026, Kevin P. Danahy, the Chief Commercial Officer of Pulse Biosciences, Inc. (the “Company”) gave notice that he was resigning from the Company, effective immediately.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PULSE BIOSCIENCES, INC.
Date: March 2, 2026	By:	/s/ Paul A. LaViolette
		Paul A. LaViolette
		President and Chief Executive Officer (Principal Executive Officer)

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.5 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 11.5 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 15.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.7 KB